Table 1.
Clinical and Laboratory Characteristics of the Study Population Subdivided in CAD and CAD‐Free Groups
| CAD‐Free Patients, n=246 | CAD Patients, n=687 | P Value* | |
|---|---|---|---|
| Age, y | 57.5±13.4 | 60.6±9.4 | <0.001 |
| Male sex, % | 71.0 | 81.0 | 0.001 |
| History of smoke, % | 43.3 | 68.9 | <0.001 |
| Hypertension, % | 34.0 | 63.4 | <0.001 |
| Diabetes, % | 6.5 | 17.1 | <0.001 |
| BMI, kg/m2 | 25.5±3.5 | 26.7±3.3 | <0.001 |
| Creatinine, mmol/L* | 89.2 (86.6 to 91.8) | 94.7 (92.9 to 96.5) | 0.001 |
| hs‐CRP, mg/L* | 1.79 (1.53 to 2.09) | 3.32 (3.04 to 3.63) | <0.001 |
| Cholesterol, mmol/L | 5.51±1.04 | 5.73±1.11 | 0.010 |
| LDL‐cholesterol, mmol/L | 3.55±0.90 | 3.83±0.97 | <0.001 |
| HDL‐cholesterol, mmol/L | 1.44±0.42 | 1.21±0.30 | <0.001 |
| Triglycerides, mmol/L* | 1.33 (1.27 to 1.40) | 1.72 (1.66 to 1.78) | <0.001 |
| Apo A, g/L | 1.43±0.28 | 1.29±0.23 | <0.001 |
| Apo B, g/L | 1.06±0.25 | 1.19±0.30 | <0.001 |
| Apo C‐III, mg/dL* | 10.2 (9.8 to 10.6) | 11.4 (11.1 to 11.7) | <0.001 |
| Apo E, g/L* | 0.040 (0.038 to 0.042) | 0.042 (0.041 to 0.043) | 0.029 |
| Statin therapy, % | 3.2 | 28.4 | <0.001 |
| FII:c, IU/dL* | 117 (113 to 122) | 126 (124 to 128) | <0.001 |
| FV:c, IU/dL* | 126 (121 to 130) | 134 (131 to 136) | 0.002 |
| FVIII:c, IU/dL | 150±48 | 171±55 | <0.001 |
| FVIIa, mU/mL* | 41.4 (38.0 to 45.1) | 44.2 (42.3 to 46.3) | 0.148 |
Apo indicates apolipoprotein; BMI, body mass index; CAD, coronary artery disease; FII:c, FV:c, and FVIII:c, coagulant activities of factor II, factor V, and factor VIII, respectively; FVIIa, activated factor VII; HDL, high‐density lipoprotein; hs‐CRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein.
*
By t test or χ2‐test.
*
Variables with a skewed distribution (ie, creatinine, hs‐CRP, triglycerides, Apo C‐III, Apo E, FII:c, FV:c, and FVIIa) were log‐transformed and then presented as geometric means with 95% confidence intervals.